These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8337547)

  • 21. Overestimation of benefit when clinical trials stop early: a simulation study.
    Liu S; Garrison SR
    Trials; 2022 Sep; 23(1):747. PubMed ID: 36064448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation following group-sequential response-adaptive clinical trials.
    Morgan CC
    Control Clin Trials; 2003 Oct; 24(5):523-43. PubMed ID: 14500051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous sequential monitoring of efficacy and safety led to masking of effects.
    van Eekelen R; de Hoop E; van der Tweel I
    J Clin Epidemiol; 2016 Aug; 76():155-65. PubMed ID: 26944293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stopping rules for phase II studies.
    Stallard N; Whitehead J; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symmetric group sequential test designs.
    Emerson SS; Fleming TR
    Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of a new multinomial phase II stopping rule using response and early progression.
    Dent S; Zee B; Dancey J; Hanauske A; Wanders J; Eisenhauer E
    J Clin Oncol; 2001 Feb; 19(3):785-91. PubMed ID: 11157032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.
    Ventz S; Cellamare M; Parmigiani G; Trippa L
    Biostatistics; 2018 Apr; 19(2):199-215. PubMed ID: 29036330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of adaptation algorithm, timing, and stopping boundaries on the performance of Bayesian response adaptive randomization in confirmative trials with a binary endpoint.
    Jiang Y; Zhao W; Durkalski-Mauldin V
    Contemp Clin Trials; 2017 Nov; 62():114-120. PubMed ID: 28866294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.
    Stone A
    Pharm Stat; 2010; 9(2):151-61. PubMed ID: 19771540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring multi-armed trials.
    Proschan MA; Follmann DA; Geller NL
    Stat Med; 1994 Jul 15-30; 13(13-14):1441-52. PubMed ID: 7973223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stopping boundaries adjusted for sample size reestimation and negative stop.
    Shun Z
    J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P-value interpretation and alpha allocation in clinical trials.
    Moyé LA
    Ann Epidemiol; 1998 Aug; 8(6):351-7. PubMed ID: 9708870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing a primary and a secondary endpoint in a group sequential design.
    Tamhane AC; Mehta CR; Liu L
    Biometrics; 2010 Dec; 66(4):1174-84. PubMed ID: 20337631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.